ReviewPharmaceutics2018
Anticancer Activity of Bacterial Proteins and Peptides.
Review in Pharmaceutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
82 citing papers in PubMed, 191 citations in OpenAlex.
- Selective cytotoxicity of microcin H47 against MDA-MB-231 breast cancer cells: an antimicrobial peptide with therapeutic potential.Archives of microbiology · 2026Article
- Microbial-Derived Anti-Cancer Compounds: Advances in Drug Discovery, Bioengineering, and Therapeutic Applications.Anti-cancer agents in medicinal chemistry · 2026Review
- Anticancer compounds from Streptomyces: insights from metagenomics and mechanistic perspective.Folia microbiologica · 2025Review
- In-Silico Exploration of the StreptomeDB Database for Potential Irreversible DprE1 Inhibitors toward Antitubercular Treatment.ChemistryOpen · 2025Article
- Key Signals Produced by Gut Microbiota Associated with Metabolic Syndrome, Cancer, Cardiovascular Diseases, and Brain Functions.International journal of molecular sciences · 2025Review
- Chondromyxoid fibroma of the lumbar spine: is tumor recurrence to be expected after subtotal resection? Illustrative case.Journal of neurosurgery. Case lessons · 2025Article
- Firmicutes in gut microbiota: hormonal influence on breast cancer in obese individuals.Discover oncology · 2025Review
- Investigation of the Protective Effect of Betaine in an Experimental Pulmonary Fibrosis Model Induced by Intratracheal Administration of Bleomycin.Journal of clinical practice and research · 2025Article
- The Production of Recombinant Azurin fromInternational journal of molecular sciences · 2025Article
- Role of TDP2 in the repair of DNA damage induced by the radiomimetic drug Bleomycin.Genes and environment : the official journal of the Japanese Environmental Mutagen Society · 2025Article
- Unveiling the pH-Responsive Mechanisms of the Carbon Dot-Proximicin-A Peptide Conjugate for Targeted Cancer Therapy Using Density Functional Theory.Molecules (Basel, Switzerland) · 2025Article
- The Enterococcus secretome inhibits the growth of vancomycin-resistant Enterococcus faecalis V853 with their antiproliferative properties and nanoencapsulation effects.International microbiology : the official journal of the Spanish Society for Microbiology · 2025Article
- Azurin a potent anticancer and antimicrobial agent isolated from a novel Pseudomonas aeruginosa strain.Scientific reports · 2025Article
- Plant-derived Bisphenol C is a drug candidate againstIn silico pharmacology · 2025Article
- Actinomycetes: A Source of Anticancer Metabolites.Current medicinal chemistry · 2025Review
- Mechanisms of Bleomycin-induced Lung Fibrosis: A Review of Therapeutic Targets and Approaches.Cell biochemistry and biophysics · 2024Review
- Transforming microbial pigment into therapeutic revelation: extraction and characterization of pyocyanin from Pseudomonas aeruginosa and its therapeutic potential as an antibacterial and anticancer agent.Microbial cell factories · 2024Article
- Two Recombinant Bacteriocins, Rhamnosin and Lysostaphin, Show Synergistic Anticancer Activity Against Gemcitabine-Resistant Cholangiocarcinoma Cell Lines.Probiotics and antimicrobial proteins · 2024Article
- Therapeutic bacteria and viruses to combat cancer: double-edged sword in cancer therapy: new insights for future.Cell communication and signaling : CCS · 2024Review
- Article
22 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite much progress in the diagnosis and treatment of cancer, tumour diseases constitute one of the main reasons of deaths worldwide. The side effects of chemotherapy and drug resistance of some cancer types belong to the significant current therapeutic problems. Hence, searching for new anticancer substances and medicines are very important. Among them, bacterial proteins and peptides are a promising group of bioactive compounds and potential anticancer drugs. Some of them, including anticancer antibiotics (actinomycin D, bleomycin, doxorubicin, mitomycin C) and diphtheria toxin, are already used in the cancer treatment, while other substances are in clinical trials (e.g., p28, arginine deiminase ADI) or tested in in vitro research. This review shows the current literature data regarding the anticancer activity of proteins and peptides originated from bacteria: antibiotics, bacteriocins, enzymes, nonribosomal peptides (NRPs), toxins and others such as azurin, p28, Entap and Pep27anal2. The special attention was paid to the still poorly understood active substances obtained from the marine sediment bacteria. In total, 37 chemical compounds or groups of compounds with antitumor properties have been described in the present article.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.